Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2003
04/02/2003EP1296929A2 Modified forms of pharmacologically active agents and uses therefor
04/02/2003EP1296722A2 Radiotherapy
04/02/2003EP1296720A2 Poliovirus replicons encoding therapeutic agents and uses thereof
04/02/2003EP1296716A2 New formulation
04/02/2003EP1296709A1 Solubilised protein vaccines
04/02/2003EP1296705A1 Neurotoxic oligomers
04/02/2003EP1296702A1 Neuroprotective peptides
04/02/2003EP1296699A1 Therapeutic agents - iii
04/02/2003EP1296698A1 Therapeutic agents - ii
04/02/2003EP1296697A1 Therapeutic agents - i
04/02/2003EP1296692A1 Use of a formulation made of or containing at least one dissimilated milk serum
04/02/2003EP1296691A2 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
04/02/2003EP1296686A2 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
04/02/2003EP1296684A2 Treatment of gastroesophageal reflux disease using piperidine derivatives
04/02/2003EP1296681A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
04/02/2003EP1296671A2 Gabapentin analogues for sleep disorders
04/02/2003EP1296670A1 Therapeutic combinations of fatty acids
04/02/2003EP1296665A1 Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
04/02/2003EP1296661A2 Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities
04/02/2003EP1296652A1 Topical pharmaceutical formulations and methods of treatment
04/02/2003EP1296650A2 Methods and compositions for treating pain of the mucous membrane
04/02/2003EP1296649A2 Pharmaceutical compositions comprising an opioid analgesic
04/02/2003EP1296644A2 Systems and methods for treating a mucosal surface
04/02/2003EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5
04/02/2003EP1228069B1 Bicyclic and tricyclic heteroaromatic compounds
04/02/2003EP1226143B1 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors
04/02/2003EP1208100B1 Selective antagonists of a2b adenosine receptors
04/02/2003EP1114051B1 INHIBITORS OF p38
04/02/2003EP1030842B1 Metalloproteinase inhibitors
04/02/2003EP1015446B1 (4-piperidinyl)-1h-2-benzopyran derivatives useful as antipsychotic agents
04/02/2003EP0954519B1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof
04/02/2003EP0951467B1 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE
04/02/2003EP0946520B1 Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
04/02/2003EP0912512B1 Sulphonamide derivatives and their use in the treatment of cns disorders
04/02/2003EP0873295B1 Dimer-selective rxr modulators and methods for their use
04/02/2003EP0770081B1 Heterocycle-condensed morphinoid derivatives
04/02/2003EP0644772B1 Opioid peptides
04/02/2003CN1407986A Novel imidazotriazinones and the use thereof
04/02/2003CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor
04/02/2003CN1407983A Tert-butyl-(7-methyl-imidazo [1,2-A] pyridine-3-yl)-amine derivatives
04/02/2003CN1407982A Serotonergic benzofurans
04/02/2003CN1407980A Heterocyclic derivatives
04/02/2003CN1407973A Butyne diol derivatives
04/02/2003CN1407972A 4-pyrimidine-N-acyl-L-phenylalanines
04/02/2003CN1407971A Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
04/02/2003CN1407970A Urea compounds having muscarinic receptor antagonist activity
04/02/2003CN1407897A DHEA composition and method
04/02/2003CN1407894A Pharmaceutical composition
04/02/2003CN1407893A Triazinone compounds for treating diseases resulting from infretation with parasitic protozoans
04/02/2003CN1407889A Flat medicinal preparation for transmucosal administration of oxycodon or comparable active ingredient in oral cavity, for use in pain therapy and in addiction therapy
04/02/2003CN1407887A Oral liquid compositions
04/02/2003CN1407884A Controlled release hydrocodone formulations
04/02/2003CN1406947A Short peptide and its derivative and medicine with them as active component and use thereof
04/02/2003CN1406624A Medicinal composition with nourishing and tranquilizing
04/02/2003CN1406592A Medicine for treating epilepsy
04/02/2003CN1406591A Medicine against aseptic inflammation by ranunculaceae plant and use thereof
04/02/2003CN1406523A Oral liquid production
04/02/2003CN1406516A Healthy food
04/02/2003CN1104432C Pyrrole triazines and pyrimidine compound
04/02/2003CN1104422C Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
04/02/2003CN1104418C Benzoheterocyclic derivatives
04/02/2003CN1104412C Benzamidine derivatives and use thereof as medicaments with LTB4-antagonistic effect
04/02/2003CN1104242C Use of epinastine in the treatment of pain
04/01/2003WO2002029054A1 Novel protein, process for producing the same and use thereof
04/01/2003US6541669 Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis
04/01/2003US6541638 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction
04/01/2003US6541637 Reacting a paroxetine with hydrogen chloride in the presence of isopropyl alcohol and crystallizing the resulting product to form paroxetine hydrochloride anhydrate, drying to reduce amount of isopropyl alcohol to 5%
04/01/2003US6541523 Methods for treating or preventing fibromyalgia using very low doses of cyclobenzaprine
04/01/2003US6541520 Treatment of addiction and addiction-related behavior
04/01/2003US6541513 Carbamate compounds for use in preventing or treating psychotic disorders
04/01/2003US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
04/01/2003US6541502 Treatment of disorders associated with dopamine dysregulation such as schizophrenia
04/01/2003US6541501 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity
04/01/2003US6541490 Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt
04/01/2003US6541489 Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1
04/01/2003US6541486 Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation.
04/01/2003US6541484 Central nervous system disorders; psychological disorders
04/01/2003US6541478 Smoking cessation treatments using naltrexone and related compounds
04/01/2003US6541475 2-nitrostyryl-1-(naphthylmethyl)sulfone for example
04/01/2003US6541471 Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist
04/01/2003US6541469 CRF receptor antagonists and methods relating thereto
04/01/2003US6541468 Treating Alzheimer's disease by inhibiting in a subject hyperphosphoralation characteristic of Alzheimer's disease by a kinase the compound
04/01/2003US6541466 Such as 1-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)-aminodibenzosuberane; for treatment of Alzheimer's disease
04/01/2003US6541457 Mammalian IAP gene family, primers, probes and detection methods
04/01/2003US6541255 Engraftable human neural stem cells
04/01/2003US6541219 Therapeutic Gene
04/01/2003US6541027 Lactic acid bacteria with anxiolytic properties and uses thereof
04/01/2003US6541021 Completely implanting in a patient, at a implntation site, a controlled release drug delivery device containing a pump and a drug selected from fentanyl and a fetanyl congener, such as sufentanil for treating the pain for atleast about 3-days
04/01/2003US6541015 Water soluble prodrug with a biologically active agent link trapped in a hydrogel and controllably released by diffusion
04/01/2003US6540393 Apparatus for preparing microparticles using in-line solvent extraction
04/01/2003CA2424777A1 Novel protein, process for producing the same and use thereof
04/01/2003CA2270975C Stabilized sustained release tramadol formulations
04/01/2003CA2217463C Use of sulbutiamine to obtain pharmaceutical compositions which are useful in the treatment of some psychomotor and psychointellectual disorders
03/2003
03/31/2003WO2002030425A1 Preventives and remedies for complications of diabetes
03/31/2003CA2424060A1 Preventives and remedies for complications of diabetes
03/28/2003WO2002030871A1 Use of amino acids for treating pain
03/28/2003WO2002030869A1 5-amino-1-pentene-3-ol substituted derivatives
03/28/2003CA2424103A1 Substituted 5-amino-1-penten-3-ol derivatives
03/28/2003CA2424089A1 Use of amino acids for treating pain
03/28/2003CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue
1 ... 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 ... 1833